Product Description: Talniflumate (BA 7602-06) is the proagent of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase[1]. Talniflumate is an orally active Ca2+-activated Cl- channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome[2].
Applications: COVID-19-immunoregulation
Formula: C21H13F3N2O4
References: [1]Hyun-Ji Kim, et al. Pharmacokinetics of talniflumate, a prodrug of niflumic acid, following oral administration to man. Archives of Pharmacal Research volume 19, Article number: 297 (1996)/[2]Mollereau, et al. Agonist and Antagonist Activities on Human NPFF(2) Receptors of the NPY Ligands GR231118 and BIBP3226. Br J Pharmacol.2001 May;133(1):1-4.
CAS Number: 66898-62-2
Molecular Weight: 414.33
Compound Purity: 99.67
Research Area: Inflammation/Immunology
Solubility: DMSO : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Chloride Channel
English
Deutsch
